Abstract
A 55 year old African American male with a medical history of diffuse large B-cell lymphoma (DLBCL) receiving chemotherapy presents for fatigue and dark red urine. Five days prior to this presentation, the patient was seen at his oncology clinic for progression of his cancer. The patient was started on a new chemotherapy regimen as well as rasburicase and allopurinol for hyperuricemia thought to be secondary to tumor lysis syndrome. Subsequent lab work indicated acute hemolytic anemia. Etiology was suspected to be hemolytic anemia triggered by rasburicase in the setting of undiagnosed G6PD deficiency. The patient recovered with supportive care including blood transfusions and cessation of rasburicase. G6PD deficiency is the most prevalent inherited erythrocyte disorder classically considered to impact populations in tropical Africa and Asia, however is estimated to impact approximately 10% of African American men. ¹⋅² This case exemplifies the importance of considering G6PD deficiency when administering medications that cause increased oxidative stress, such as rasburicase, in addition to the swift recognition and management of subsequent complications.
Publisher
Department of Medicine, Warren Alpert Medical School at Brown University
Reference20 articles.
1. Management of Rasburicase-Induced Hemolytic Anemia;D.A. Kaland;Journal of Hematology Oncology Pharmacy,2018
2. Glucose 6 phosphate dehydrogenase deficiency unmasked by diabetic ketoacidosis: An underrated phenomenon;Ayushi Agarwal;Journal of Clinical and Diagnostic Research,2013
3. Methemoglobinemia in patient with G6PD deficiency and SARS-COV-2 infection;Kieran Palmer;Emerging Infectious Diseases,2020
4. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase;Mohamad Bassam Sonbol;American Journal of Hematology,2012
5. Methemoglobinemia: pathogenesis, diagnosis, and management;Anna Skold;Southern Medical Journal,2011